S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
MarketBeat Week in Review – 3/20 - 3/24
Urgent Warning (Ad)
Bank failures and rescue test Yellen's decades of experience
Germany, EU reach agreement in combustion engine row
Modern Day Options Trading For Beginners! (Ad)pixel
Intel co-founder, philanthropist Gordon Moore dies at 94
'What can we do?': Millions in African countries need power
Modern Day Options Trading For Beginners! (Ad)pixel
Judge rules online archive's book service violated copyright
Renamed Horseshoe to host Poker World Series on Vegas Strip
NASDAQ:CNCE

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

$8.37
+0.01 (+0.12%)
(As of 03/6/2023)
Add
Compare
Today's Range
$8.35
$8.55
50-Day Range
$6.90
$8.40
52-Week Range
$2.66
$8.55
Volume
10.73 million shs
Average Volume
2.97 million shs
Market Capitalization
$401.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
150.9% Upside
$21.00 Price Target
Short Interest
Healthy
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
0.32mentions of Concert Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$350,763 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.70) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.55 out of 5 stars

Medical Sector

125th out of 1,005 stocks

Pharmaceutical Preparations Industry

51st out of 486 stocks


CNCE stock logo

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Concert Pharma: Q3 Earnings Insights
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Company Calendar

Last Earnings
11/09/2021
Today
3/25/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+150.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$-80,050,000.00
Pretax Margin
-300,735.69%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.24 per share

Miscellaneous

Free Float
42,507,000
Market Cap
$401.26 million
Optionable
Optionable
Beta
0.52

Key Executives

  • Roger D. TungRoger D. Tung
    President, Chief Executive Officer & Director
  • Nancy StuartNancy Stuart
    Chief Operating Officer
  • Marc A. BeckerMarc A. Becker
    Chief Financial & Accounting Officer
  • Mitch K. Goldenberg
    VP-Information Technology & Infrastructure
  • Virginia Braman
    Vice President-Clinical Development













CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CNCE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CNCE, but not buy additional shares or sell existing shares.
View CNCE analyst ratings
or view top-rated stocks.

What is Concert Pharmaceuticals' stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price objectives for Concert Pharmaceuticals' stock. Their CNCE share price forecasts range from $17.00 to $25.00. On average, they expect the company's stock price to reach $21.00 in the next year. This suggests a possible upside of 150.9% from the stock's current price.
View analysts price targets for CNCE
or view top-rated stocks among Wall Street analysts.

How have CNCE shares performed in 2023?

Concert Pharmaceuticals' stock was trading at $5.84 at the start of the year. Since then, CNCE shares have increased by 43.3% and is now trading at $8.37.
View the best growth stocks for 2023 here
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analysts' expectations of $0.25 million. During the same quarter last year, the company posted ($0.60) earnings per share.

What ETFs hold Concert Pharmaceuticals' stock?

ETFs with the largest weight of Concert Pharmaceuticals (NASDAQ:CNCE) stock in their portfolio include iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?
What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (3.61%), Millennium Management LLC (3.01%), Point72 Asset Management L.P. (2.80%), Bank of America Corp DE (2.73%), Ingalls & Snyder LLC (2.70%) and Tang Capital Management LLC (2.40%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Peter Barton Hutt and Roger D Tung.
View institutional ownership trends
.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $8.37.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $401.26 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 3/25/2023 by MarketBeat.com Staff